CMMB News and Press, Chemomab Therapeutics Ltd. From 08/12/22

Chemomab Therapeutics Ltd. (CMMB) Q2 2022 Earnings Conference Call August 12, 2022 08:00 ET CompanyParticipants Barbara Lindheim - Consulting Vice President Investor & Public Relations Dale Pfost - Chairman & Chief Executive Officer David Weiner - Interim...

Chemomab Therapeutics - ADR press release ( NASDAQ: CMMB ): Q2 GAAP EPS of -$0.027. Cash, cash equivalents and bank deposits were $51.8 million as of June 30, 2022, compared to $57.5 million at March 31, 2022. For further details see: Chemomab Therapeutics -...

Chemomab Adds Highly Experienced Executives Further Strengthening Its R&D and Clinical Capabilities Chemomab Adds Highly Experienced Executives Further Strengthening Its R&D and Clinical Capabilities PR Newswire ─Appoints Ilan Vaknin, PhD, as Vice Pr...

Chemomab Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update PR Newswire ─ Chemomab to Host Webcast and Conference Call for Investors Today, August 12 at 8:00 am ET ─ TEL AVIV, Israel , ...

Chemomab Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update PR Newswire TEL AVIV, Israel , Aug. 1, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd . (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology comp...

Chemomab Therapeutics (NASDAQ:CMMB), a clinical-stage biotech focused on inflammation and fibrosis, added ~7% in the pre-market Tuesday after the company announced that the U.S. regulators issued a new patent covering its lead drug candidate CM-101. A monoclonal antibody, CM-101, is...

Chemomab Presents Data Further Supporting the Mechanism of Action and Potential Efficacy of CM-101 in Primary Sclerosing Cholangitis PR Newswire —Data Presented at 2022 EASL International Liver Conference TM and First International  Extracellular Matrix...

Chemomab Therapeutics to Present at June Investor and Scientific Conferences PR Newswire TEL AVIV, Israel , June 9, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd . (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the disc...

Data Supporting Role of Chemomab's Novel Therapeutic Target CCL24 in Systemic Sclerosis Presented at EULAR 2022 PR Newswire —Poster Presentation of Reverse Translational Study Data Using Patient Samples Supports Role of CCL24 as a Therapeutic Target for Systemic...

The following slide deck was published by Chemomab Therapeutics Ltd. in conjunction with this event. For further details see: Chemomab Therapeutics (CMMB) Investor Presentation - Slideshow